AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

30 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

26 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

13 Nov 2024 09:49:44 By NetDania Notify

NetDania - New 12 months High: AXSOME THERAPEUTICS INC. - COMMON STOCK

12 Nov 2024 10:02:19 By NetDania Notify

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

12 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

08 Nov 2024 07:00:28 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

29 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

15 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024

24 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

04 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Participate in Investor Conferences in September

27 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

21 Aug 2024 07:00:39 By Nasdaq GlobeNewswire

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

05 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

11 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

05 Jun 2024 07:35:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month

04 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics to Participate in Upcoming Investor Conferences

30 May 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting

28 May 2024 07:00:00 By Nasdaq GlobeNewswire